Ann Dermatol.  2017 Dec;29(6):794-795. 10.5021/ad.2017.29.6.794.

Paradoxical Flare of Psoriasis after Ustekinumab Therapy

• Lee HY
• Woo CH
• Haw S

• KMID: 2395192
• DOI: http://doi.org/10.5021/ad.2017.29.6.794

Abstract

No abstract available.

MeSH Terms

Psoriasis*
Ustekinumab*
Ustekinumab

Figure

• 

  Fig. 1 Before the second ustekinumab injection. Skin lesion was dramatically improved.

• 

  Fig. 2 (A, B) Paradoxical flare of plaque type psoriasis after the fourth injection.

Reference

1. Benson JM, Sachs CW, Treacy G, Zhou H, Pendley CE, Brodmerkel CM, et al. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol. 2011; 29:615–624.

2. Famenini S, Wu JJ. The safety of ustekinumab in psoriasis. J Drugs Dermatol. 2012; 11:907–910.

3. Wenk KS, Claros JM, Ehrlich A. Flare of pustular psoriasis after initiating ustekinumab therapy. J Dermatolog Treat. 2012; 23:212–214.

4. Hay RA, Pan JY. Paradoxical flare of pustular psoriasis triggered by ustekinumab, which responded to adalimumab therapy. Clin Exp Dermatol. 2014; 39:751–752.

5. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009; 20:100–108.